POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS IN ADULT AND PEDIATRIC RENAL TRANSPLANT PATIENTS RECEIVING TACROLIMUS-BASED IMMUNOSUPPRESSION1 RON SHAPIRO,2.3 MICHAEL NALESNIK,4 JERRY MCCAULEY,2 SHEILA FEDOREK,2 MARK L. JORDAN,5 VELMA P. SCANTLEBURY,2 AsHOK JAIN,2 CARLOS VIVAS,5 DEMETRIUS ELLIS,6 SUSANNE LOMBARDOZZI-LAl"lE,6 PARMJEET RANDHAWA,4 JAMES JOHNSTON,7 THOMAS

نویسندگان

  • RON SHAPIRO
  • MICHAEL NALESNIK
  • SHEILA FEDOREK
  • MARK
  • JORDAN
  • VELMA P. SCANTLEBURY
  • AsHOK JAIN
  • CARLOS VIVAS
  • DEMETRIUS ELLIS
  • PARMJEET RANDHAWA
  • JAMES JOHNSTON
  • THOMAS R. HAKALA
  • RICHARD
  • SIMMONS
  • S JOHN J. FUNG
  • THOMAS E. STARZL
چکیده

Between March 27, 1989 and December 31, 1997, 1316 kidney transplantations alone were performed under tacrolimus-based immunosuppression at our center. Posttransplant lymphoproliferative disorders (PTLD) developed in 25 (1.9%) cases; the incidence in adults was 1.20/c (1511217). whereas in pediatric patients it was 10.IO/c (10/99; P<.OOOl). PTLD was diagnosed 21.0±22.5 months after transplantation, 25.0±24.7 months in adults and 14.4±18.2 months in pediatric patients. Of the 4 adult cases in whom both the donor and recipient Epstein Barr virus (EBV) serologies were known, 2 (50%) were seropositive donor -> seronegative recipient. Of 7 pediatric cases in whom both the donor and recipient EBV serologies were known, 6 (860/d were EBV seropositive donor -> seronegative recipient. Acute rejection was observed before the diagnosis ofPTLD in 8 (53%) of 15 adults and 3 (30%) of 10 pediatric patients. Initial treatment of PTLD included a marked decrease or cessation of immunosuppression with concomitant ganciclovir therapy; two adults and two pediatric patients required chemotherapy_ With a mean follow-up of 24_9±30.1 months after transplantation. the 1and 5-year actuarial patient and graft survival rates in adults were 930/c and 860/c. and 80lf( and 60%, respectively. Two adults died, 3.7 and 46.2 months after transplantation, of complications related to PTLD, and 10 (including the 2 deaths) lost their allograft 3.7-84.7 months after transplantation. In children, the 1and 5-year actuarial patient and graft survival rates were 1000/, and 100'7.:, and 100% and H90/c, respectively. No child died; one child lost his allograft 41.3 months after transplantation. One child had presumed recurrent PTLD that responded to discontinuation of tacrolimus and reinitiation of antiviral therapy. The mean serum creatinine level in adults was 2.5±1.2 mg/dl. and in children. it was 1.3±0.6 mg/ dl. Under tacrolimus-based immunosuppression. PTLD is less common after renal transplantation in

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Pediatric renal transplantation under tacrolimus-based immunosuppression.

BACKGROUND Tacrolimus has been used as a primary immunosuppressive agent in adult and pediatric renal transplant recipients, with reasonable outcomes. Methods. Between December 14, 1989 and December 31, 1996, 82 pediatric renal transplantations alone were performed under tacrolimus-based immunosuppression without induction anti-lymphocyte antibody therapy. Patients undergoing concomitant or pri...

متن کامل

Posttransplant diabetes in pediatric recipients on tacrolimus.

We read with interest the report by Moxey-Mims et aI., "Increased Incidence of Insulin-Dependent Diabetes Mellitus in Pediatric Renal Transplant Patients Receiving Tacrolimus (FK506)," reporting a 100% incidence of posttransplant diabetes mellitus in five pediatric patients receiving tacrolimusbased immunosuppression after renal transplantation (1). Although posttransplant diabetes mellitus (PT...

متن کامل

Tacrolimus-based immunosuppression in pediatric renal transplantation.

TACROLIMUS has been shown to be a safe and effective immunosuppressive agent in adult renal transplantation with significant advantages, including the ability to taper corticosteroids in up to 65% of recipients. 1-4 The use of this agent in the pediatric population is less well described. We and others have previously reported that its use in pediatric patients is associated with excellent pati...

متن کامل

Rituximab Is Indispensable for Pediatric Heart Transplant Recipients Developing Post transplant Lymphoproliferative Disorders

Abstract Rituximab, an anti-CD20 agent, has been suggested as an effective strategy to deal with post transplant lymphoproliferative disorders (PTLD). In the current study, we aim to evaluate the efficacy of rituximab therapy in heart transplant population developing PTLD. A comprehensive search of the literature was performed to gather the available data on lymphoproliferative disorders oc...

متن کامل

A prospective randomized trial of FK506-based immunosuppression after renal transplantation.

A group of 204 adult patients was entered into a prospective, randomized trial comparing FK506/prednisone with FK506/azathioprine/prednisone after renal transplantation between August 1, 1991 and October 11, 1992. The purpose of the study was to see if the addition of azathioprine would reduce the incidence of rejection and improve graft survival. The recipient population was unselected, with 6...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2010